Tech Company Financing Transactions

Neumora Therapeutics Funding Round

On 10/11/2022, Neumora Therapeutics raised $112 million in Series B funding from Abu Dhabi Fund for Development, Altitude Life Science Ventures and Amgen Ventures.

Transaction Overview

Company Name
Neumora Therapeutics
Announced On
10/11/2022
Transaction Type
Venture Equity
Amount
$112,000,000
Round
Series B
Investors

Abu Dhabi Fund for Development (Lead Investor)

Altitude Life Science Ventures (Lead Investor)

Amgen Ventures (Lead Investor)

Arch Venture Partners (Lead Investor)

EXOR (Lead Investor)

F-Prime Capital (Lead Investor)

Invus (Lead Investor)

Mubadala (Lead Investor)

Polaris Partners (Lead Investor)

New Path Ventures

Proceeds Purpose
The company intends to use the funds to support the advancement of a broad clinical and preclinical pipeline of novel precision medicine candidates for neuropsychiatric disorders and neurodegenerative diseases and the development of the its precision neuroscience platform.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
490 Arsenal Way 200
Watertown, MA 02472
USA
Phone
Undisclosed
Website
www.neumoratx.com
Email Address
Not Recorded
Overview
Neumora was founded to improve the lives of patients with brain diseases. A significant challenge is a lack of targeted, effective medicines. Neumora is relentless in its commitment to discovering, developing, and commercializing targeted therapies for people living with brain diseases.
Profile
Neumora Therapeutics LinkedIn Company Profile
Social Media
Neumora Therapeutics Company Twitter Account
Company News
Neumora Therapeutics News
Facebook
Neumora Therapeutics on Facebook
YouTube
Neumora Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Paul Berns
  Paul Berns LinkedIn Profile  Paul Berns Twitter Account  Paul Berns News  Paul Berns on Facebook
Chief Financial Officer
Joshua Pinto
  Joshua Pinto LinkedIn Profile  Joshua Pinto Twitter Account  Joshua Pinto News  Joshua Pinto on Facebook
Chief Medical Officer
Jane Tiller
  Jane Tiller LinkedIn Profile  Jane Tiller Twitter Account  Jane Tiller News  Jane Tiller on Facebook
Chief Scientific Officer
Nick Brandon
  Nick Brandon LinkedIn Profile  Nick Brandon Twitter Account  Nick Brandon News  Nick Brandon on Facebook
Co-Founder
Mike Poole
  Mike Poole LinkedIn Profile  Mike Poole Twitter Account  Mike Poole News  Mike Poole on Facebook
Vice President
Otute Akiti
  Otute Akiti LinkedIn Profile  Otute Akiti Twitter Account  Otute Akiti News  Otute Akiti on Facebook
VP - Bus. Development
Mary Chamberlain-Tharp
  Mary Chamberlain-Tharp LinkedIn Profile  Mary Chamberlain-Tharp Twitter Account  Mary Chamberlain-Tharp News  Mary Chamberlain-Tharp on Facebook
VP - Bus. Development
Carol Suh
  Carol Suh LinkedIn Profile  Carol Suh Twitter Account  Carol Suh News  Carol Suh on Facebook
VP - General Counsel
Tammy Tompkins
  Tammy Tompkins LinkedIn Profile  Tammy Tompkins Twitter Account  Tammy Tompkins News  Tammy Tompkins on Facebook
VP - Human Resources
Amy Sullivan
  Amy Sullivan LinkedIn Profile  Amy Sullivan Twitter Account  Amy Sullivan News  Amy Sullivan on Facebook
VP - R & D
John Dunlop
  John Dunlop LinkedIn Profile  John Dunlop Twitter Account  John Dunlop News  John Dunlop on Facebook
VP - Regulatory Affairs
Bill Aurora
  Bill Aurora LinkedIn Profile  Bill Aurora Twitter Account  Bill Aurora News  Bill Aurora on Facebook
VP - Regulatory Affairs
Lori Houle
  Lori Houle LinkedIn Profile  Lori Houle Twitter Account  Lori Houle News  Lori Houle on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/11/2022: Adyton venture capital transaction
Next: 10/11/2022: NumberOne AI venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.